Market Overview

Benzinga's Top Downgrades

Benzinga's Top Downgrades
Related BMY
FDA Decisions In November: The Month In Review
A Lazarus Act For This Pharma ETF
Your Daily Pharma Scoop: Conatus Looks Undervalued, Teva Announces Restructuring, Bristol-Myers Signs Licensing Agreement (Seeking Alpha)
Related HOG
Benzinga's Bulls And Bears Of The Past Week: Chevron, Coach, Ford, PayPal And More
Harley-Davidson Hogging All The Market Share It Can
Harley-Davidson goes ex-dividend tomorrow (Seeking Alpha)

Analysts at Barclays downgraded Bristol-Myers Squibb Company (NYSE: BMY) from “overweight” to “equal-weight.” The target price for Bristol-Myers Squibb has been lowered from $65 to $46. Bristol-Myers Squibb's shares closed at $48.12 yesterday.

Analysts at Raymond James downgraded Harley-Davidson (NYSE: HOG) from “strong buy” to “market perform” and removed the price target of $84. Harley-Davidson's shares closed at $70.33 yesterday.

Baird downgraded U.S. Bancorp (NYSE: USB) from “outperform” to “neutral.” The price target for U.S. Bancorp is set to $44. U.S. Bancorp's shares closed at $43.34 yesterday.

Credit Suisse downgraded Hormel Foods (NYSE: HRL) from “outperform” to “neutral.” Hormel's shares closed at $49.19 yesterday.

Latest Ratings for BMY

Oct 2017Credit SuisseMaintainsNeutral
Oct 2017Leerink SwannMaintainsOutperform
Oct 2017CitigroupMaintainsBuy

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings


Related Articles (BMY + HOG)

View Comments and Join the Discussion!

Partner Center